Digital Marketing Trends in Severe Asthma
All the vital news, analysis, and commentary curated by our industry experts.
Digital Marketing Trends in Asthma Report Overview
Sanofi/Regeneron’s Dupixent.com achieved the highest total traffic across branded asthma patient sites in the US and branded asthma HCP sites in the US from June 2022 to May 2023. In addition, there were a few unbranded asthma sites detected in the US. Amgen/AstraZeneca’s Breakthecycle.com had the highest level of traffic from June 2022 to May 2023 with more than 180,000 visits. Between June 2022 and May 2023, over 200 social media posts related to asthma were detected in the US from pharma companies, including Sanofi, Amgen, GSK, Teva, and Regeneron.
This report assesses key digital marketing metrics of pharma assets in asthma, including branded websites for patients and healthcare professionals (HCPs), unbranded websites, and social media accounts. Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), and social media post interaction. Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).
|Digital Marketing Trends in Asthma (US)||Branded Asthma Patient Sites, Branded Asthma HCP Sites, Unbranded Asthma Sites, Social Media Posts Related to Asthma|
|Digital Marketing Trends in Asthma (EUCAN)||Branded Asthma Sites, Unbranded Asthma Websites, Social Media Posts Related to Asthma|
|Key Traffic Generation by Source||Direct, Organic, Referral, Paid, and Social|
|Key Publishers||Google DV360, Google Display Network, Direct Buy, Amazon Advertising, AppNexus, YouTube, and Others|
|Enquire & Decide||Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.|
Digital Marketing Trends in Asthma in the US
The key digital marketing trends in Asthma in the US are branded asthma patient sites, branded asthma HCP sites, unbranded asthma sites, and social media posts related to asthma.
Top US Branded Patient Websites: Some of the key US branded patient websites garnering some of the highest traffic and engagement online were Dupixent.com, Trelegy.com, Nucala.com, Xolair.com, Tezspire.com, Mybreo.com, Mysymbicort.com, and Fasenra.com. During June 2022-May 2023, Sanofi/Regeneron’s Dupixent.com achieved the highest total traffic across branded asthma patient sites in the US, with over 5.7 million visitors, followed by GSK’s Trelegy.com (2.5 million visits) and Nucala.com (1.4 million visits).
Top US Branded Patient Websites by Traffic and Engagement, June 2022-May 2023 (%)
For more traffic and engagement insights on the top branded patient websites in the US, download a free sample report
Top US Branded Patient Websites by Traffic Source: Some of the top sources being used to generate traffic toward the top US branded patient websites are direct, organic, referral, paid, and social. Overall, the highest proportion of traffic to top branded patient asthma websites originated from direct sources, followed by organic. Sanofi/Regeneron’s Dupixent.com had the highest level of direct traffic (78%), followed by Trelegy.com (71%).
Top US Branded Patient Websites by Source, June 2022-May 2023 (%)
For more source insights on the top branded patient websites in the US, download a free sample report
Top US Branded Patient Websites by Paid SEO, DDA Spending, and Publishers: The highest paid SEO was for AstraZeneca’s Tezspire.com with more than 55,000 keywords, followed by Dupixent.com with over 12,000 keywords. Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $5.9 million, followed by GSK’s Trelegy.com ($3.4 million) and AstraZeneca’s Treszpire.com ($1 million). The top publisher of ads across the 12-month period was Google DV360 at approximately $4.8 million, followed by YouTube and Google Display Network.
Top US Branded Patient Websites by Publisher, June 2022-May 2023 (%)
For more publisher insights on the top branded patient websites in the US, download a free sample report
Top US Branded HCP Websites: Sanofi/Regeneron’s Dupixenthcp.com achieved the highest total traffic across branded asthma HCP sites in the US, with almost 3.4 million visitors from June 2022 to May 2023. This was followed by GSK’s Trelegyhcp.com (2.8 million visits) and Nucalahcp.com (1.3 million visits). In terms of traffic generation by source, the highest proportion of traffic to branded asthma websites for HCPs originated from paid sources, followed by organic and direct. The highest paid SEO was for Dupixenthcp.com with more than 29,500 keywords, followed by Tezspirehcp.com with over 15,000 keywords.
Top US Branded HCP Websites by Traffic Source, June 2022-May 2023 (%)
For more traffic source insights on the top branded HCP websites in the US, download a free sample report
Top US Unbranded Sites: Few unbranded asthma sites were detected in the US. Between June 2022 and May 2023, Amgen/AstraZeneca’s Breakthecycle.com had the highest level of traffic with more than 180,000 visits. This was followed by GSK’s Asthma.com with more than 100,000 visits and Sanofi/Regeneron’s Type2inflammation.com with more than 70,000 visits. Overall, the highest proportion of traffic to unbranded asthma websites originated from direct sources, followed by organic and paid traffic. Breakthecycle.com had the highest proportion of traffic from direct searches (85%), while Type2inflammation.com had the highest organic (45%) and referral (11%) traffic. GSK’s Asthma.com had the highest paid traffic (31%).
US Social Media Activity in Asthma
Between June 2022 and May 2023, 205 social media posts related to asthma were detected in the US from pharma companies, including Amgen, GSK, Sanofi, Teva, and Regeneron. Amgen had the highest number of asthma-related posts on its corporate Twitter account (65 posts); the post with the highest interaction (<0.1%) highlighted different asthma organizations that Amgen operates.
US Social Media Activity in Asthma, June 2022-May 2023 (%)
To know more about the social media activity in Asthma in the US, download a free sample report
EUCAN Website Insights
EUCAN Branded Websites Total Traffic and Engagement Metrics: Few branded asthma sites were detected in EUCAN. There were only two sites with notable traffic between June 2022 – May 2023, AstraZeneca’s Symbiocort.ca with over 42,000 visits and Sanofi/Regeneron’s Dupixent.ca with over 2,000 visits. Traffic engagement metrics were similar for the two sites. Dupixent.ca had a higher average visit duration of 14 minutes and 46 seconds, while Symbicort.ca had a slightly lower bounce rate (94%).
EUCAN Unbranded Websites Total Traffic and Traffic Source: Between June 2022 and May 2023, there were similar levels of total traffic to GSK’s Ilmiorespiro.it and Novartis’s Asthma.de (572,000–577,000 visits), followed by Chiesi’s Smallairways.es with more than 240,000 visits. Overall, the highest proportion of traffic to unbranded asthma websites originated from direct sources, followed by organic and paid traffic.
EUCAN Social Media Activity in Asthma: Between June 2022 and May 2023, over 620 social media posts related to asthma were detected in EUCAN from pharma companies, including Sanofi, GSK, Chiesi, Teva, and AstraZeneca. Sanofi posted the most asthma content overall, with over 290 posts across its various local language corporate accounts, the majority of which were from its Sanofi Espana Twitter account (120 posts).
For more insights on the EUCAN website insights, download a free sample report
- This report assesses key digital marketing metrics of pharma assets in severe asthma, including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts.
- Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads, and social media post interaction.
- Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).
Reasons to Buy
- Understand the digital marketing competitive landscape in asthma, with a view of leading patient and HCP branded assets across different regions.
- See what tactics pharma companies are using to drive traffic to their asthma branded and unbranded assets for patient and HCPs, such as DDA and paid SEO.
- Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
- Compare top branded assets for patients by how they address and support different patient needs.
- See what pharma social media accounts in asthma are the most active and achieving the most engagement.
Table of Contents
US Patient Branded Websites
US HCP Branded Websites
US Unbranded Websites
US Social Media
EUCAN Branded Websites
EUCAN Unbranded Websites
EUCAN Social Media
Frequently asked questions
Which US-branded patient website accounted for the highest traffic during June 2022-May 2023?
Sanofi/Regeneron’s Dupixent.com achieved the highest total traffic across branded asthma patient sites in the US.
Which US-branded patient website had the largest traffic source during June 2022-May 2023?
The highest proportion of traffic to top branded patient asthma websites originated from direct sources.
What were the Top US Branded Patient Websites publishers during June 2022-May 2023?
The top publisher of ads across the 12-month period was Google DV360.
Which pharma company had the highest social media posts during June 2022-May 2023?
Amgen had the highest number of asthma-related posts on its corporate Twitter account.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.